Therapeutic prospects of naturally occurring p38 MAPK inhibitors tanshinone IIA and pinocembrin for the treatment of SARS‐CoV‐2‐induced CNS complications

Abstract

AbstractP38 mitogen‐activated protein kinase (p38 MAPK) signaling pathway is closely related to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) replication and hyperinflammatory responses in coronavirus disease 2019 (COVID‐19). Therefore, blood–brain barrier‐penetrating p38 MAPK inhibitors have good potential for the treatment of central nervous system (CNS) complications of COVID‐19. The aim of the present study is the characterization of the therapeutic potential of tanshinone IIA and pinocembrin for the treatment of CNS complications of COVID‐19. Studies published in high‐quality journals indexed in databases Scopus, Web of Science, PubMed, and so forth were used to review the therapeutic capabilities of selected compounds. In continuation of our previous efforts to identify agents with favorable activity/toxicity profiles for the treatment of COVID‐19, tanshinone IIA and pinocembrin were identified with a high ability to penetrate the CNS. Considering the nature of the study, no specific time frame was determined for the selection of studies, but the focus was strongly on studies published after the emergence of COVID‐19. By describing the association of COVID‐19‐induced CNS disorders with p38 MAPK pathway disruption, this study concludes that tanshinone IIA and pinocembrin have great potential for better treatment of these complications. The inclusion of these compounds in the drug regimen of COVID‐19 patients requires confirmation of their effectiveness through the conduction of high‐quality clinical trials.